CClinicalTrials.gg
RecruitingNCT04451265DACODACUpdated Jan 5, 2026

Diagnostic Accuracy of Optimized Diffusion-Weighted Imaging for Detecting Anterior Ischemic Optic Neuropathy

An observational study in Neuro-Ophthalmology, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

From the registry’s dates

  • Started Oct 2022; still recruiting 3 years 11 months later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Study summary

The patient presents to the ophthalmological emergencies and / or to the internal medicine department. NOIA clinical discovery Patient referred in radiology for brain and visual MRI. The two sequences added by the research (8 minutes) will be added to that of the treatment.

02

Conditions studied

  • Neuro-Ophthalmology
03

In context

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 311 studies on the registry; 77 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients with suspected NOIA, discussed after clinical examination by a specialist ophthalmologist

Inclusion criteria

  • Patient over 18 years old
  • Patient with suspected NOIA, evoked after clinical examination by a specialized ophthalmologist
  • For which a brain and visual MRI is planned
  • Express consent to participate in the study
  • Affiliate or beneficiary of a Social Security scheme

Exclusion criteria

Exclusion Criteria:

  • Contraindication to MRI (electrical device, metallic foreign body, claustrophobia)
  • Patient benefiting from a legal protection measure
  • Pregnant or breastfeeding woman
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Interventions

  • OtherMRI

    Diffusion sequence (8 minutes long) added to the initial MRI

06

What researchers measure

Primary outcomes

  1. Study the sensitivity of the High resolution Diffusion sequence in the detection of NOIA, evaluated by a DWI hypersignal and an ADC hyposignal of the optic nerve

    Time frame: basline

07

Study locations

1 of 3 sites recruiting
  • CHU de LILLE
    Lille, Lille 59000, France
    Not yet recruiting
  • Fondation A De Rothschild
    Paris, PARIS 75019, France
    • Amelie YAVCHITZ · Contact · ayavchitz@for.paris · 0148036431
    • Candice Sabben, MD, PhD · Principal investigator
    • Pierre Seners, MD, PhD · Principal investigator
    Recruiting
  • Chu Rouen
    Rouen, 76100, France
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04451265
Lead sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Responsible party
Sponsor
First posted
Jun 30, 2020
Start date
Oct 26, 2022
Primary completion
Sep 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Jan 5, 2026

Study contacts

Amelie YAVCHITZ
Contact
ayavchitz@for.paris
0148036431
sidney krystal
Contact
skrystal@for.paris
0148036401

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion